Sutureless Perceval (Liva Nova, Saluggia, Italia) Aortic Valve in High Risk Aortic Patients. A Key Tool for the Cardiac Surgeon

Elisabet Berastegui Garcia ¹, Sara Badia Gamarra ¹, Maria Luisa Camara Rosell ¹, Luis Delgado Ramis ¹, Claudio Fernandez Gallego ¹, Anna Llorens Ferrer ¹, Ignasi Julia Almill ¹, Juan Bustamante Munguira  ², Bernat Romero Ferrer  ¹, Christian Muñoz Guijosa ¹

¹ Hospital Universitari Germans Trias i Pujol , BAdalona, Spain; ² Hospital Universitari Germans Trias i Pujol , Girona , Spain;

Date, time and location: 2018.05.25 15:30, Exhibition area, 1st Floor. Zone – D

Abstract

The development of new surgical techniques AND AORTIC PROSTHESES has reduced the risk associated with aortic valve replacement procedures. We present the results on surgical outcomes and hemodynamics in moderate and high risk patients, after the beginning of a sutureless aortic valve replacement programme.

Patients and Method:

Prospectively collected data of 348 patients undergoing aortic valve replacement with Perceval sutureless prosthesis. (LIVA NOVA, SALUGGIA, ITALY) from November 2013 to November 2017.

Results:

The mean age was 77.9 YEARS (SD 6,02 years). 48.8% were octogenarians. 55.4 % were women. The estimated EuroSCORE I log risk was 13.27% (SD 10 %);II 8,4 % in hospital observed mortality was 5.49 % (n=20 patients). In 30.2 % of patients a mini-sternotomy approach was employed. 30% of patients underwent a concomitant procedure. 31 patients (8.9%) required implantation of a permanent pacemaker after the procedure. 3 patients presented a cerebrovascular accident. At discharge 6 patients (1.7%) presented minimal periprosthetic leakage and 2 patients (0.5%) presented moderate leakage. The mean follow-up was 22 ± 3 months. There were 3 re-interventions during follow-up: 2 due to endocarditis and 1 VALVEdislocation after AN INTERVENTIONAL procedure. The mean gradient at discharge, first, second and third year was: 14.2mmHg; 12.2mmHg and 13.2mmHg respectively.The survival rate at discharge, one, two and three years was 94%, 99%, 91%, 89.5% and 98.4% respectively. There was no valve migration or early structural degeneration.

Conclusions:

The use of the Perceval SUTURELESS bioprosthesis for surgical treatment of severe aortic stenosis has shown to be feasible, reproducible,safe and effective. It is associated with low mortality and excellent hemodynamic results. There were no valve migrations, structural valve degeneration or valve thrombosis in the follow up.